Certainty of genuine treatment increases drug responses among intellectually disabled patients

Conclusions:
Our data suggest that clinical trials in patients with severe cognitive deficits are influenced by the certainty of receiving genuine medication, and open-label design should thus not be used to evaluate the effect of pharmacologic treatments in ID, as the results will be biased by an enhanced placebo component.

Source: Neurology - May 15, 2017 Category: Neurology Authors: Jensen, K. B., Kirsch, I., Ponten, M., Rosen, A., Yang, K., Gollub, R. L., des Portes, V., Kaptchuk, T. J., Curie, A. Tags: Intelligence, Executive function, Clinical trials Systematic review/meta analysis, Developmental disorders, Mental retardation ARTICLE Source Type: research